Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 3
2019 1
2020 1
2021 3
2022 1
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
The Lancet Breast Cancer Commission.
Coles CE, Earl H, Anderson BO, Barrios CH, Bienz M, Bliss JM, Cameron DA, Cardoso F, Cui W, Francis PA, Jagsi R, Knaul FM, McIntosh SA, Phillips KA, Radbruch L, Thompson MK, André F, Abraham JE, Bhattacharya IS, Franzoi MA, Drewett L, Fulton A, Kazmi F, Inbah Rajah D, Mutebi M, Ng D, Ng S, Olopade OI, Rosa WE, Rubasingham J, Spence D, Stobart H, Vargas Enciso V, Vaz-Luis I, Villarreal-Garza C; Lancet Breast Cancer Commission. Coles CE, et al. Among authors: kazmi f. Lancet. 2024 Apr 12:S0140-6736(24)00747-5. doi: 10.1016/S0140-6736(24)00747-5. Online ahead of print. Lancet. 2024. PMID: 38636533 Review. No abstract available.
A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301).
Spiliopoulou P, Kazmi F, Aroldi F, Holmes T, Thompson D, Griffiths L, Qi C, Parkes M, Lord S, Veal GJ, Harrison DJ, Coyle VM, Graham J, Jeffry Evans TR, Blagden SP. Spiliopoulou P, et al. Among authors: kazmi f. J Exp Clin Cancer Res. 2024 Apr 2;43(1):100. doi: 10.1186/s13046-024-03010-1. J Exp Clin Cancer Res. 2024. PMID: 38566164 Free PMC article. Clinical Trial.
Early phase antitumour clinical trials and palliative medicine.
Virani F, Carey M, Kazmi F, Blagden S, Lord S, Miller M. Virani F, et al. Among authors: kazmi f. BMJ Support Palliat Care. 2024 Jan 8;13(e3):e780-e781. doi: 10.1136/spcare-2023-004496. BMJ Support Palliat Care. 2024. PMID: 37507202 No abstract available.
The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial.
Schwenzer H, De Zan E, Elshani M, van Stiphout R, Kudsy M, Morris J, Ferrari V, Um IH, Chettle J, Kazmi F, Campo L, Easton A, Nijman S, Serpi M, Symeonides S, Plummer R, Harrison DJ, Bond G, Blagden SP. Schwenzer H, et al. Among authors: kazmi f. Clin Cancer Res. 2021 Dec 1;27(23):6500-6513. doi: 10.1158/1078-0432.CCR-21-1652. Epub 2021 Sep 8. Clin Cancer Res. 2021. PMID: 34497073 Free PMC article.
A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma.
Booth SW, Eyre TA, Whittaker J, Campo L, Wang LM, Soilleux E, Royston D, Rees G, Kesavan M, Hildyard C, Kazmi F, La Thangue N, Kerr D, Middleton MR, Collins GP. Booth SW, et al. Among authors: kazmi f. BMC Cancer. 2021 Jul 23;21(1):851. doi: 10.1186/s12885-021-08595-w. BMC Cancer. 2021. PMID: 34301221 Free PMC article. Clinical Trial.
11 results